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Persistent bone impairment 
despite long‑term control 
of hyperprolactinemia 
and hypogonadism in men 
and women with prolactinomas
Lukas Andereggen1,7, Janine Frey2, Robert H. Andres1, Markus M. Luedi3, 
Hans Rudolf Widmer1, Jürgen Beck4, Luigi Mariani5 & Emanuel Christ6*
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes 
to determining whether correction of hyperprolactinemia and associated hypogandism improves 
osteodensitometric data in men and women over the long term. In a large cohort of including 40 men 
and 60 women, we studied the long‑term impact of prolactinoma treatment on bone mineral density 
(BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, 
and evaluated data for risk factors for impaired BMD at last follow‑up using multivariate regression 
analyses. Median duration of follow‑up was 79 months (range 13–408 months). Our data indicate 
that the prevalence of impaired BMD remained significantly higher in men (37%) than in women 
(7%, p < 0.001), despite the fact that hyperprolactinemia and hypogonadism are under control in 
the majority of men. We found that persistent hyperprolactinemia and male sex were independent 
risk factors for long‑term bone impairment. Currently, osteoporosis prevention and treatment focus 
primarily on women, yet special attention to bone loss in men with prolactinomas is advised. Bone 
impairment as “end organ” reflects the full range of the disease and could become a surrogate marker 
for the severity of long‑lasting hyperprolactinemia and associated hypogonadism.
Impaired bone mineral density (BMD) is associated with post-menopausal  women1–3, but is often underdiag-
nosed in  men4–6. Prolactinoma patients have high bone turnover, impairing  BMD7–9. Hyperprolactinemia and 
the associated hypogonadism may cause secondary  osteoporosis10–13, which has been related to skeletal fragility 
in both men and  women14, 15. While some data indicate that hyperprolactinemic subjects do not demonstrate 
increased fractures despite their low bone  density16, other studies have reported a higher prevalence of vertebral 
fractures in particular in postmenopausal women with untreated prolactinomas, compared to patients treated 
with dopamine agonists (DAs)15. However, there is a lack of evidence that normalization of prolactin levels 
improves BMD or reduces the fracture  risk17.
Likewise, it remains unclear whether prolactin (PRL) plays an independent role, separate from gonadal status, 
in the impairment of BMD, and whether controlling both improves bone  health9,14, 18, 19. While prolactin excess 
per se may contribute to skeletal  fragility9, the effects of hyperprolactinemia on gonadal function or on bone 
might be independent of gonadal  function20. Namely, normalization of prolactin and restoration of gonadal 
function might increase bone density, but this has not been associated with normalization of bone  mass21, or 
reduction of fracture  risk22.
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We hypothesized that correction of hyperprolactinemia and associated hypogonadism improves osteoden-
sitometric data in both men and women over the long-term. In a large cohort study in a dedicated tertiary 
referral center, we thus investigated whether prolactinoma treatment has an impact on the prevalence of bone 
impairment in both sexes over the long-term, and we assessed risk factors for impaired BMD that might guide 
better-targeted therapies.
Results
Patient characteristics at baseline. Between 1997 and 2015, osteodensitometric data were assessed in 
one hundred prolactinoma patients (40 men, 60 women) at Bern University Hospital at study entry and at long-
term follow-up (> 12 months). Patient characteristics are summarized in Table 1.
At baseline, men were significantly older than women, showed significantly higher median PRL levels, higher 
mean BMI, and higher prevalence of impaired BMD, and presented predominantly with headache. Of the 28% 
men with impaired BMD, 21% suffered from osteopenia and 7% from osteoporosis, whereas the 2% of women 
with impaired BMD all suffered from osteopenia and none fulfilled the criteria for osteoporosis. Macroprolac-
tinomas and cavernous sinus infiltration were more commonly seen in men than in women. Secondary adrenal 
deficiencies were noted significantly more often in men, whereas secondary hypothyroidism and gonadotropin 
deficiency were not significantly different between men and women. A primary surgical approach was performed 
in 41 women (68%) and in 12 men (30%).
Early results. At 4 ± 2.9 months (± SD), serum PRL values had decreased significantly in both cohorts, from 
1979  μg/L (IQR 768–6875) to 68  μg/L (IQR 12–282, p < 0.001) in men and from 152  μg/L (IQR 89–268) to 
15.2 μg/L (IQR 7–51, p < 0.001) in women. Overall, serum PRL values remained significantly higher in men than 
in women (p = 0.001). PRL values were in the normal range in 68% of women versus 36% of men (p = 0.002). 
At early follow-up, serum PRL levels remained significantly higher in patients with impaired baseline BMD 
(126 μg/L; IQR, 20–755) compared to those with normal baseline BMD (19 μg/L; IQR, 7–79; p = 0.05).
Long‑term results. The median long-term follow-up was 79 months (range 13–408) and was not signifi-
cantly different between the sexes (p = 0.14).
At last follow-up, impaired BMD was recorded in 37% of men and 7% of women (p < 0.001; Fig. 1A).
At this time point, 26% of men and 2% of women suffered from osteopenia, whereas 11% of men and 5% of 
women suffered from osteoporosis (Table 2).
Compared to baseline, there was no significant increase in the prevalence of impaired BMD in men (28% vs. 
37%, p = 0.47) or in women (2% vs. 7%, p = 0.21) and the prevalence of both osteopenia (9% vs .12%, p = 0.66) and 
osteoporosis (3% vs. 7%, p = 0.17) showed a non-significant increase. No pathological fractures were documented 
in our patient cohort. While the overall prevalence of impaired BMD (i.e., in both men and women) was 12% at 
baseline, it had increased to 19% by the last follow-up (p = 0.24), independent of the primary treatment strategy; 
i.e. surgical (4% vs 12%, p = 0.16) or medical (21% vs .27%, p = 0.63) treatment.
The prevalence of bone impairment at last follow-up was significantly higher in patients with persistent 
hyperprolactinemia than those with normoprolactinemia (42% vs. 15%; p = 0.04); in hypogonadal compared 
Table 1.  Patient characteristics at baseline. IQR interquartile range, SEM standard error of the mean, SD 
standard deviation, yrs years, n number. Bold values are statistically significant for p = 0.05; significance level 
was set at 5%.
Men Women Total p value
Number of patients, n (%) 40 (40) 60 (60) 100 (100)
Age at diagnosis in years (mean ± SD) 46.6 ± 14.8 34.3 ± 11.5 39.2 ± 14.2 < 0.001
BMI (kg/m2 ± SD) 28.7 ± 4.6 25.5 ± 5.6 26.9 ± 5.4 0.008
Treatment, n (ratio)
Medical: surgical 28/12 (2:1) 19/41 (1:2) 47/53 n/a
Headache, n (%) 17 (43) 12 (20) 29 (29) 0.02
Affected pituitary axes, n (%)
Gonadotropin deficiency 16 (84) 44 (92) 60 (90) 0.39
Secondary hypothyroidism 4 (13) 4 (7) 8 (9) 0.45
Secondary adrenal insufficiency 4 (12) 1 (2) 5 (5) 0.05
Tumor size, n (%)
Macroadenoma 32 (80) 21 (35) 53 (53) < 0.001
Microadenoma 8 (20) 39 (65) 47 (47) < 0.001
Tumor invasiveness 32 (80) 5 (9) 37 (39) < 0.001
Prolactin levels in μg/L (median; IQR) 1978.5 (768–6875) 152 (88–268) 252.6 (110–1704) < 0.001
Impaired bone mineral density 11 (28) 1 (2) 12 (12) < 0.001
Follow-up time in months (mean ± SEM) 81.6 ± 9.3 114.2 ± 12.5 101 ± 8.5 0.14
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with eugonadal patients (33% vs. 10%; p = 0.01); and in patients with persistent sex hormone therapy compared 
to those without (46% vs. 10%; p < 0.001). There was no significant increase in the prevalence of bone impairment 
in patients without DA agonist therapy compared to those with persistent need for DA agonists (16% vs. 20%; 
p = 0.79). Regarding the adenoma size, the prevalence of bone impairment was significantly greater in patients 
with macroadenomas than in patients with microadenomas at baseline (19% vs. 4%, p = 0.03), but not at last 
follow-up (26% vs. 11%, p = 0.07).
Total testosterone levels in men significantly increased, namely form 5.9 ± 4.8 nnoml/l at baseline to 
13.3 ± 3.6 nmol/l in the long-term (p = 0.001). Likewise, estradiol levels in women significantly increased, from 
62 ± 68 pg/ml at baseline to 161 ± 371 pg/ml in the long-term (p = 0.003).
The duration of clinical symptom onset reported prior to diagnosis was 18 ± 69 months (± SD). The calculated 
duration of hyperprolactinemia and hypogonadism was 41 ± 82 months and 38 ± 98 months, respectively. Thereby, 
Figure 1.  (A) Prevalence of bone impairment in both sexes. Significantly more men with prolactinomas 
suffered from bone impairment, both at baseline (28 vs. 2%, p < 0.001) and at last follow-up (37 vs. 7%, 
p < 0.001), compared to women. (B) Kaplan–Meier estimation of recurrence-free intervals. The median (± SD) 
recurrence-free intervals were significantly shorter in patients with impaired BMD (179 ± 72 months) than in 
those with normal BMD (396 ± 117 months; log-rank test, p = 0.04).
Table 2.  Characteristics of patients with impaired bone mineral density. OP osteopenia, OO osteoporosis, S 
lumbar spine, F femoral bone, T tibia, n no specifications, repl. Replacement, B/V/C bisphosphonate/vitamin 
D/calcium, FU follow-up, med medical, surg surgical, M male, F female.



















1 M Med OP (S,F) Normal No No No No 9155 93.4 13.8 No
2 M Med OP (S,F) OP (S,F) Yes No Yes Yes 19,200 2.1 4.5 No
3 M Med OO (S,F,T) OO (S,F,T) No No No Yes 41,920 50.4 40.7 No
4 M Med OP (S,F,T) OP (S,F,T) No No Yes No 4422 6.6 2.8 No
5 M Surg OP (S,F,T) OO (S,F,T) No Yes Yes Yes 6473 877 0.5 No
6 M Med OP (S,F), OO (T)
OP (S,F), 
OO (T) No No Yes Yes 31,940 918 172 No
7 M Med OP (S,F,T) OP (S,F,T) No No Yes Yes 29,687 418.9 195.9 No
8 M Med OO (S), OP (F,T)
OO (S), OP 
(F,T) No No YES Yes 791 63.2 12.8 Yes
9 M Med OP (T) OP (T) No No Yes Yes 12,480 857 10.4 Yes
10 M Med OP (S,T) OP (S,T) No No Yes Yes 1510 447.5 22.8 Yes
11 M Surg OP (S,F,T) OP (S,F,T) No No No Yes 79.7 9.4 24.8 No
12 M Surg Normal OP (n) No No Yes No 130 76.8 11.9 No
13 M Med Normal OP (S,F) No No Yes No 1718 112.4 59.8 No
14 M Surg Normal OP (n) No No No No 1080 12.3 11.7 No
15 M Med Normal OP (S,F,T) No No Yes Yes 9160 231 29.4 No
16 F Med OP (S) OP (S) No No No Yes 83.4 158.7 n/a No
17 F Med Normal OO (S,F,T) No no Yes No 105 34 7 No
18 F Surg Normal OO (S) No No Yes Yes 465 11.3 48.3 Yes
19 F Surg Normal OO (S) No No Yes Yes 70.4 17.1 17 No
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the duration of hyperprolactinemia in patients with impaired bone density was greater over the long-term than 
in patients with normal bone density, although this was not significant (33 ± 100 months vs. 86 ± 90 months, 
p = 0.24). Similarly, the duration of hypogonadism was greater in patients with impaired bone density than in 
those with normal BMD, although this was not significant (104 ± 84 months vs. 38 ± 81 months, p = 0.15). In 
particular, there was no significant difference between the sexes in the time that patients remained hypogonadal; 
this measured 40 ± 66 months in men versus 33 ± 114 months in women (p = 0.29).
In patients with resolution of hyperprolactinemia, the time to performance of bone densitometry was 
47 ± 64 months, with a longer time period in men than in women, although this was not statistically significant 
(31 ± 58 months vs. 57 ± 67 months; p = 0.06).
PRL levels had normalized in most patients by the long-term follow-up, independent of gender (men vs. 
women; 82% vs. 89%, p = 0.37). Nevertheless, significantly fewer women required DA agonists for the long-term 
control of hyperprolactinemia than men (75 vs. 42%, p = 0.001). Also, PRL levels had normalized independent 
of the primary treatment approach (surgery vs. DAs; 92% vs. 80% p = 0.14). We noted that significantly fewer 
patients in the surgical versus medical cohort required DA agonists over the long-term (32% vs. 79%, p < 0.001). 
Gonadotropin deficiency significantly improved both in men and women (same p < 0.001), as did headache 
(p < 0.001 and p = 0.02, respectively). Secondary hypothyroidism and secondary adrenal insufficiency improved 
in both groups, although not significantly. In 41 (68%) premenopausal women with available data confirming 
amenorrhea at baseline, no significant association between duration of amenorrhea and long-term BMD status 
was noted (r = 0.20, p = 0.08). In addition, the duration of amenorrhea in women was not a risk factor for impaired 
BMD at last follow-up (OR 1.0, 95%CI 1.0–1.1; p = 0.32). Furthermore, the amount of time between resolution 
of hyperprolactinemia and the performance of bone densitometry was not a risk factor for impaired BMD at 
last follow-up (OR 1.0, 95% CI 1.0–1.1, p = 0.14).
Of the 100 patients assessed with DXA, only one patient with osteopenia at baseline was noted with a normal 
BMD over the long-term (patient number 1, Table 2). While a normal BMD status was noted both at baseline and 
at last follow-up in 82 patients, seven of those patients with initially normal BMD demonstrated impaired BMD 
over the long-term. In addition, in eight patients osteopenia was noted both at baseline and over the long-term, 
as was osteoporosis in two further patients. Thus, persistent bone impairment in patients with prolactinomas 
was common, despite long-term control of hyperprolactinemia and hypogonadism in the majority of them. As a 
result, of the 12 patients with low bone density at baseline (OP and OO), 11 also had low BMD in the long-term, 
and deterioration was noted in an additional 7 patients.
At last follow-up, recurrence of prolactinoma was observed in 35% of patients with an impaired BMD com-
pared to 22% of patients with a normal BMD (p = 0.35). Specifically, the recurrence rate was 36% in men and 33% 
in women with an impaired BMD, and 17% in men vs. 24% in women with normal BMD (p = 0.76). In addition, 
recurrence of a prolactinoma was noted in 20% of patients with upfront surgery compared to 30% of patients 
treated with DAs (p = 0.25). There was no significant difference in the recurrence-free intervals of prolactinomas 
between men and women (178 ± 18 months vs. 288 ± 28 months; log-rank test, p = 0.25). However, the median 
(± SD) recurrence-free intervals were significantly shorter in patients with impaired BMD (179 ± 72 months) 
than in those with normal BMD (396 ± 117 months; log-rank test, p = 0.04, Fig. 1B).
The risk factors associated with long-term bone impairment are summarized in Table 3. Significant risk fac-
tors in the univariable analysis were: patient age, male sex, persistent hyperprolactinemia including length of 
hyperprolactinemia, and persistent hypogonadism. The multivariable logistic regression revealed male sex (OR 
16.4, 95% CI 2.4–114.3, p = 0.01) and persistent hyperprolactinemia (OR 5.6, 95% CI 1.0–32.5, p = 0.05), but not 
persistent hypogonadism (OR 3.1, 95% CI 0.8–12.4, p = 0.12) or primary treatment strategy (OR 1.2, 95% CI 
0.3–5.2, p = 0.81) as independent risk factors for long-term bone impairment (Table 3).
Table 3.  Risk factors for impaired BMD at last follow-up in patients with prolactinomas. BMI body mass 
index, DA dopamine, FU follow-up, iBMD impaired bone mineral density. Bold values are statistically 
significant for p = 0.05; significance level was set at 5%.
Risk factors for iBMD at last FU Univariable analyses OR (95% CI) p value Multivariable analyses OR (95% CI) p value
Age, years 1.1 (1.0–1.1) 0.01 1.0 (1.0–1.1) 0.66
Sex: men 8.0 (2.4–26.9) 0.001 16.4 (2.4–114.3) 0.01
Primary medical approach 2.8 (1.0–8.2) 0.06 1.2 (0.3–5.2) 0.81
BMI at baseline 1.0 (0.9–1.1) 0.46
Tumor size (e.g., macroadenoma) 2.8 (0.9–8.6) 0.07 2.0 (0.4–10.9) 0.41
BMI at last FU 1.0 (0.9–1.1) 0.86
Persistent need for DA-agonists 1.3 (0.5–3.7) 0.61
Persistent hyperprolactinemia 4.2 (1.2–15.5) 0.03 5.6 (1.0–32.5) 0.05
Persistent hypogonadism 4.8 (1.6–14.4) 0.006 3.1 (0.8–12.4) 0.12
Follow-up time, months 1.0 (0.9–1.0) 0.17
Length of hypogonadism 1.0 (1.0–1.1) 0.15
Length of hypperprolactinemia 1.0 (1.0–1.1) 0.26
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Morbidity and mortality. There was no mortality in either cohort. Postoperative complications in the 
surgical group consisted of transient rhinoliquorrhea (3%), syndrome of inappropriate antidiuretic hormone 
(SIADH) secretion (12%), and diabetes insipidus (13%). In the medical group, prolonged nausea occurred in 9% 
of patients, dopamine agonist-induced impulse control disorders were observed in two men (4%)23, and vertigo 
in 3% of patients with no difference between men and woman.
Discussion
This large prolactinoma cohort study shows that: (1) although both hyperprolactinemia and hypogonadism 
are under control in the majority of patients at a median follow-up of ≈ 7 years, the prevalence of bone impair-
ment was and continues to be significantly higher in men than in women; (2) persistent hyperprolactinemia 
and male sex, but not persistent hypogonadism, are independent risk factors for long-term bone impairment in 
prolactinoma patients; and (3) recurrence-free intervals are significantly shorter in prolactinoma patients with 
impaired BMD.
Long‑term impact of prolactinoma treatment on bone mineral density. Hyperprolactinemia and 
the associated hypogonadism affect bone turnover in prolactinoma  patients10, 14, 15. While age-related bone loss 
might have contributed to bone fragility over our study period of almost seven years to some  extent24, 25, long-
lasting hyperprolactinemia has been found to be a major contributor to bone impairment, even when hyper-
prolactinemia is brought under  control15, 20, corroborating our results. Consistently, treatment with DA agonists 
over 2 years was not found to restore bone impairment in young patients suffering from  hyperprolactinemia12.
We further noted that significantly more men than women suffered from bone impairment at study entry.
While amenorrhea in women is easily detected and investigated, men often do not report the more non-
specific symptoms of hypogonadism, such as loss of libido. Consequently, women probably suffer from hyper-
prolactinemia and hypogonadism over a much shorter period before diagnosis, and treatment is initiated much 
earlier than for  men26. This hypothesis is further supported by the current finding that the age at diagnosis was 
significantly higher for men than for women. Likewise, macroprolactinomas were more frequently encountered 
in men than in women, possibly contributing to both the higher baseline PRL levels as well as the subsequent 
higher prevalence of bone impairment in men compared to women. Namely, initial prolactin levels and the size 
of the tumor may reflect how long the disease has been present, given that bone loss has been associated with 
the duration of amenorrhea in women with  prolactinomas8. Nevertheless, in this study cohort, the duration of 
therapy or the duration of amenorrhea in women was not a significant risk factor for BMD development. Fur-
thermore, treatment of the prolactinoma might interfere with BMD development. Conversely, while couldn’t 
observe a difference in testosterone replacement, vitamin D supplementation, or the use of hydrocortisone in 
men versus women, it is conceivable that a certain selection bias towards the screening of osteoporosis in more 
severely affected men with prolactinoma took place at study entry, with 3:2 ratio of women to men. This may 
partly be explained by the fact that the prevalence of prolactinoma is known to be higher in women than in 
 men27, 28. In addition, although health insurance in Switzerland covers medical investigation and therapy, deci-
sions regarding whether to screen for bone density are not based on financial considerations. Bone measure-
ment and programs for osteoporosis prevention have mainly focused on post-menopausal  women8, 9, while this 
condition often remains underdiagnosed in  men10–12. Consistently, in a large study cohort, significantly fewer 
men received evaluation for osteoporosis following a distal radial fracture, with rates of evaluation unacceptably 
low according to published  guidelines12.
In the context of prolactinomas, the need for awareness of bone loss in both sexes might thus have been 
underestimated in men, with those affected more severely being preferentially assessed. Thus, screening of bone 
loss in both sexes should not be underestimated in prolactinoma patients, regardless of the primary treatment 
chosen (i.e., surgical or medical), as the primary treatment did not seem to influence the prevalence of bone 
impairment in our cohort.
Recurrence rates of prolactinomas. We noted no differences in the recurrence rates between men and 
women after DA agonist withdrawal, whereas other authors reported more recurrences in men than  women29, 
possibly because men suffer more often from macroprolactinomas than women  do30. While recurrence-free 
intervals were not significantly different with regard to adenoma size, patients with impaired BMD had sig-
nificantly shorter recurrence-free intervals than those with normal BMD. This is an intriguing finding. It is 
conceivable that the smaller sample size of patients with macroadenomas conceals a true  effect31. Indeed, macro-
prolactinomas in men are associated with longer lasting hyperprolactinemia and related hypogonadism, with 
subsequently impaired  BMD11, 32. Nevertheless, the adenoma size per se might not be the only factor that deter-
mines the severity of the disease. In contrast, impaired BMD, which as “end organ” reflects the full range of the 
disease, including duration of hypogonadism, might thus become a more comprehensive surrogate marker for 
the severity of long-lasting hyperprolactinemia. Given that osteoporosis prevention has particularly focused on 
postmenopausal women (with prolactinomas), assessment of BMD in men with prolactinomas might become 
routine and incorporated into study guidelines. Further studies should be directed at how to improve bone 
health in prolactinoma patients in general and how to better evaluate patients at risk at the earliest time point 
possible.
Study limitations
This study suffers from the limitations of any retrospective study, and of the single-center design. In 83 of 100 
patients, data was available on the onset of symptoms prior to diagnosis. Thus, the duration of hypogonadism 
and hyperprolactinemia, or the time period between resolution of hyperprolactinemia and the performance 
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of bone densitometry, could not be retrieved for all patients. In addition, it reflects an approximate estimation 
of the duration of both hypogonadism and hyperprolactinoemia. In addition, a true effect for the association 
between amenorrhea duration and long-term BMD status might have been concealed given the sample size of 
premenopausal women with available data confirming amenorrhea at baseline.
Given that there was no prospective assessment of DA-induced impulse control disorders, the true number of 
patients experiencing them might be underestimated. Likewise, although severe personality changes have been 
reported, these might often not be mentioned by the patients due to feelings of  shame12.
No treatments with growth hormones (GH) were noted in this cohort, and not all patients werescreened for 
growth hormone (GH) deficiency using validated dynamic testing, or for vitamin D concentrations and active 
smoking status, so it is possible that these parameters influenced the bone health status in some  patients33–38. 
Patients with osteopenia and osteoporosis have been grouped together as patients with impaired BMD, and 
statistical uncertainty in this sample size precluded us from discriminating between osteopenia and osteopo-
rosis in both men and women. Numeric BMD values in this patient cohort are missing, thus quantification of 
bone improvement following treatment of hyperprolactinoma and hypogonadism was not possible. Allocation 
into groups (i.e. normal, osteopenia, osteoporosis) indirectly reflects changes in bone impairment. This pool-
ing doesn’t incorporate the fact that osteopenia is present in about 15% of young, healthy  women39. Likewise, 
using multiple logistic regression analysis to assess independent predictors influencing BMD—such as location 
of BMD measurement, testosterone replacement, vitamin D supplementation, and use of hydrocortisone (see 
Table 2)—was not statistically feasible. In addition, the location used for BMD measurement with DXA was not 
consistent in all patients examined. Although there is a significant correlation for BMD values between anatomi-
cal regions such as the spine, proximal femur and forearm, the validity of DXA measurement in prolactinoma 
patients favors the spine only, as data show that femoral BMD measurement might mask BMD effects exerted 
by hyperprolactinemia and associated  hypogonadism8, 40.
Our biochemical definition of persistent hypogonadism (i.e. inadequate gonadotropins in the presence of low 
estradiol) may have underestimated a true association between persistent hypogonadism and long-term BMD 
status, as it doesn’t incorporate those women with sporadic normal estradiol levels at follow-up, but ongoing 
oligomenorrhea.
Conclusions
The prevalence of bone impairment is and continues to be significantly higher in men with prolactinomas than 
in women. Impaired BMD as “end organ” reflects the full range of the disease and could become a surrogate 
marker for the severity of long-term hyperprolactinemia and associated hypogonadism.
Methods
This retrospective cohort study included all consecutive prolactinoma patients with osteodensitometric data at 
study entry and at long-term follow-up (> 12 months) who were treated at our tertiary referral center between 
1997 and 2015. All patients fulfilled the diagnostic criteria of a prolactin (PRL)-secreting pituitary adenoma (i.e., 
PRL levels > 30 µg/L without evidence of pituitary stalk compression, primary hypothyroidism or drug-induced 
hyperprolactinemia), and had a positive pituitary magnetic resonance imaging (MRI) scan. The indication for 
first-line pituitary surgery was local complications of the adenomas or the patient’s preference to undergo sur-
gery rather than long-term DA agonist therapy, as reported  previously11, 41. Each patient’s situation and primary 
treatment were discussed at the interdisciplinary pituitary tumor board meeting.
BMD was assessed by dual-energy X-ray absorptiometry (DXA, HOLOGIC, Bedford, MA, USA) at the 
femoral bone and/or spine at baseline and at last follow-up. A T-score ≥ 1 SD was regarded as normal, whereas 
a T-score of − 1.5 to − 2.5 SD suggested osteopenia, and ≤ −2.5 SD suggested osteoporosis. The Z-score was used 
in the diagnosis of impaired BMD in premenopausal women and in men aged < 50  years42, 43. Impaired BMD 
was considered in patients with osteopenia and/or  osteoporosis11, 44.
MRI was performed on a 1.5-T or 3-T system including a Proton/T2-weighted whole-brain study with 
unenhanced, contrast-enhanced, dynamic contrast-enhanced and post contrast-enhanced overlapping studies 
in the axial, sagittal and coronal planes over the sellar  region45, 46. A tumor with a diameter of 1–10 mm was 
defined as a microadenoma, and a tumor > 10 mm in diameter was defined as a macroadenoma. Infiltration of 
the cavernous sinus was defined as ≥ two-thirds encasement of the internal carotid artery by the adenoma, as 
previously  described47, 48.
Patient characteristics recorded at study entry included age, body mass index (BMI), co-occurring clinical 
symptoms such as headache, pituitary axes deficits and radiological findings. Symptoms such as galactorrhea 
and amenorrhea in women or infertility and/or lack of libido or erectile dysfunction in men were noted sepa-
rately. Partial hypopituitarism was defined as impaired secretion of one or more pituitary hormones. PRL levels 
were assessed. These included the immunoradiometric PRL assay with serum dilution in order to overcome the 
high-dose PRL hook  effect49–52. Secondary adrenal insufficiency was noted in the presence of low cortisol levels 
in the serum or in cases where cortisol level was normal but responses to the adrenocorticotropic hormone 
(ACTH) stimulation test or insulin tolerance test were inadequate. The diagnosis of secondary hypothyroidism 
was made in the presence of low-normal thyrotropin (TSH) levels and a low free thyroxin (FT4) level. Hypog-
onadotropic hypogonadism, or central hypogonadism, leads to secondary amenorrhea or irregular menstrual 
cycle in female patients and impaired libido in males. Biochemically, inadequately normal-low gonadotropins 
can be documented, resulting in lack of production of estradiol or  testosterone53, 54.
For men, two fasting measurements of total testosterone concentrations were used for the screening for andro-
gen  deficiency55, 56. Blood samples were collected after overnight fasting. Serum concentrations of total testoster-
one (normal reference range, 9.9–28.0 nmol/L) were measured using the Elecsys-System (ROCHE diagnostics, 
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Rotkreuz, Switzerland) as well as the Centaur-System (BAYER diagnostics, Zürich, Switzerland)57. To evaluate 
the day-to-day variance, total testosterone was measured by the Elecsys-System on two different days within one 
month at 8 am in the fasting  state58.
In order to estimate the duration of hyperprolactinemia and subsequent hypogonadism, we reviewed patients’ 
records in order to assess the reported onset of clinical symptoms prior to diagnosis (i.e., onset of galactorrhea/
amenorrhea in women; loss of libido or erectile dysfunction in men). The estimated duration of hyperprolactine-
mia and hypogonadism was then calculated from the date of reported onset of symptoms to the date of laboratory 
correction of hyperprolactinemia or hypogonadism during the follow-up visit.
Pituitary surgery (n = 53) was performed using a transseptal, transsphenoidal microsurgical approach, as 
described  previously45, 59. Postoperatively, body weight, fluid intake and output, serum electrolytes, and serum 
and urine osmolality were monitored daily. An antibiotic was administered in the perioperative setting and 
discontinued after 24 h.
Early follow-up took place about three months after surgery or at the initiation of DA agonist treatment. The 
dose of the DA agonist was increased if PRL levels were still elevated (> 30 µg/L) in the medical cohort. If patients 
in the surgical cohort had elevated PRL at pathological levels, DA agonist therapy was initiated.
A standardized protocol was followed for the withdrawal of DA agonists. In the medical cohort, DA agonists 
were tapered 24 months after initiation of the medical therapy if PRL levels had normalized and tumor reduction 
of > 50% was attained at the time of radiological follow-up, as defined  previously60, 61. Recurrence was defined 
as an increase in PRL levels above the normal range (> 25 µg/L for women, > 20 µg/L for men) during the last 
follow-up period after a previous remission, irrespective of radiological  findings62, 63.
Statistical analysis. Data were analyzed using IBM SPSS statistical software Version 24.0 (IBM Corp., New 
York, NY, USA) and visualized using GraphPad Prism (V7.03 software, San Diego, CA, USA). Continuous vari-
ables were examined for homogeneity of variance and are expressed as mean ± SD except where otherwise noted. 
PRL levels are presented as median values and interquartile range (IQR, 25th–75th percentile). For comparisons 
of means between two groups, Student’s t-test was used for normally distributed data, and the Mann–Whitney 
test for nonparametric data. The Wilcoxon signed-rank test was used to evaluate paired differences in PRL, tes-
tosterone and estradiol levels before and after  treatment64. Categorical variables were compared using Pearson’s 
chi-square test or Fisher’s exact test, as  appropriate65. The Kaplan–Meier method was used to analyze recur-
rence-free intervals during follow-up, and significance was calculated using the log-rank (Mantel–Cox) test. 
To identify potential associations with impaired BMD at last follow-up, possible risk factors (patient age, sex, 
primary therapeutic approach, BMI, initial tumor size [i.e. macroadenoma], persistent need for DA agonists, 
persistent hyperprolactinemia and hypogonadism) were included, and multivariate analysis was performed with 
a binary logistic regression model. OR and 95% CI were calculated and p values ≤ 0.05 were considered statisti-
cally  significant66, 67.
Ethical standards and patient consent. All methods were performed in accordance with the relevant 
guidelines and regulations of Scientific Reports. The study is a retrospective data project using existing data to 
evaluate registry data quality, and there was no any patient contact for the study, therefore there was no patient 
consent process. The Human Research Ethics Committee of Bern (Kantonale Ethikkommision KEK Bern, Bern, 
Switzerland) approved the project (KEK no. 10-10-2006 and 8-11-2006). The ethics commit waived the need for 
informed consent for this study as part of the study approval. The study was performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Data availability
The authors agree to share data on request.
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